A B S T R A C T Patients with systemic lupus erythematosus (SLE) were found to have in their plasma antibodies specific for desialized T cells. Adsorption studies with intact or desialized T cells indicated that SLE anti-T cell antibodies consisted of two populations with different target cell specificities, one capable of recognizing unique determinants on desialized T cells and another able to bind to both intact and desialized T cells. Normal T cells did not remove the antibodies specific for desialized T cells. Moreover, the antibodies to desialized T cells were not removed by adsorption with either desialized non-T cells or desialized erythrocytes. Thus, the antibodies to desialized T cells recognize a determinant that is unique to a T cell subset and also includes a sugar. Inhibition studies with various sugars indicated that lactose was the most potent inhibitor of antibody binding. The anti-desialized T cell antibody appears to recognize a T cell determinant which includes lactose, probably in the form of a ,Bgalactosyl residue, but which also includes additional T cell determinants.
INTRODUCTION
Recent studies of our own (1-3) and those of others (4) (5) (6) (7) (8) (9) (10) (11) have demonstrated in both humans and mice that masking the cell surface by sialic acid occurs with T cell maturation; relatively immature T cells have a low sialic acid content and include cells involved in suppressor effector functions. Helper T cells consist of more mature T cells which have abundant sialic acid residues on the cell surface.
Numerous reports have documented the occurrence of anti-T cell antibodies in active systemic lupus erythematosus (SLE)l (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) . A subset of such antibodies preferentially interfere with a T cell necessary for the generation of suppressor cell activity, probably by killing suppressor precursor cells or their initiator cells I Abbreviations used in this paper: Con A, concanavalin A; PBS, phosphate-buffered saline; SLE, systemic lupus erythematosus.
or both (20, 21) . Analysis of natural occurring anti-T cell antibodies of New Zealand mice has shown that anti-T cell antibodies directed at intact T cells, differ from those directed at desialized T cells (23) . The present studies were carried out to investigate the possibility that some SLE anti-T cell antibodies might preferentially interact with desialized T cells. We found that such SLE anti-T cell antibodies exist. Moreover, they specifically bind to and kill functional suppressor effector cells. These antibodies to desialized T cells recognize a different T cell subset from those to intact T cells; the latter recognize a cell necessary for the generation of suppressor cells, but not mature suppressor cells (21) .
METHODS
Isolation of T cells, non-T cells, and monocytes. Mononuclear cells from the peripheral blood of healthy human donors were isolated by Ficoll-Hypaque centrifugation. T cells, non-T cells, and monocytes were separated from the mononuclear cells as previously described in detail (20, 21, 24) . Briefly, spontaneous rosette formation between human lymphocytes and sheep erythrocytes was performed with neuraminidase treated sheep erythrocytes. The rosetting cells were separated on another Ficoll-Hypaque gradient from the nonrosetting cells. Both the rosetting and nonrosetting cell fractions were further purified by repeated rosette formation with sheep erythrocytes and subsequent density gradient centrifugation. The doubly purified rosetting cell population was recovered after lysis of sheep erythrocytes by a Tris-buffered ammonium chloride solution. This population consisted of >95% T cells, as determined by rerosetting, and will be referred to as T cells. The doubly purified nonrosetting population is referred to as non-T cells and contains B lymphocytes, monocytes, and possibly other cell types. The percentage of T cell contamination in the non-T cell population was <1%, as determined by rerosetting. Monocytes were obtained by incubating the non-T cells on petri dishes for 2 h at 37°C, and collecting the cells adhering firmly to the dishes. Monocyte (20, 21, 25) . The active patients in this study had at least three of the above criteria for activity; in addition, they all had high titers of antibodies to native DNA (20, 21, 25) . Lymphocytes and plasma from the patients with active disease were obtained for in vitro studies before any treatment. Inactive patients had been previously treated with corticosteroids and occasionally with immunosuppressive drugs, but were not receiving such treatment at the time of study. All SLE plasma used had been fresh frozen and had not been previously thawed. All plasma were centrifuged at 105,000 g for 2 h at 4°C to remove aggregated materials before use.
Treatment of T cells with enzymes. 1 X 107 normal T cells were suspended in 1 ml of Hanks' balanced salt solution containing 10 mM Hepes buffer, pH 7.0. 1 ml of the cell suspension was mixed with 0.1 U of Vibrio comma neuraminidase (N-acyl-neuraminyl-glycohydrolase, 3.2.1.18 from Vibrio comma (Cholerae); Behring Institut, Marburg, West Germany) for 1 h at 370C. More than 98% of the T cells after neuraminidase treatment were found to be stained with fluorescein-conjugated peanut agglutinin (E * Y Laboratories, Inc., San Mateo, CA), which indicates that sialic acid residues were almost completely removed from the cell surfaces. T cells were treated with either papain (Sigma Chemical Co., St. Louis, MO) (60 Mg/ml of the cell suspension) or trypsin (Difco Laboratories, Inc., Detroit, MI) (20 and 200 ,ug/ml of the cell suspension) under similar conditions. Pronase (pronase-P; Kaken Chemical Co., Tokyo, Japan) (50 and 200 ug/ml of the cell suspension) treatment was performed at room temperature for 10 min. After treatment with various enzymes, these cells were washed three times in phosphate buffered saline (PBS).
Adsorption of SLE plasma with normal T cells, non-T cells, or erythrocytes, either intact or neuraminidase treated. SLE Assay of suppressor cell function. Suppressor T cells were generated by concanavalin A (Con A) activation in a first culture as previously described (20, 21, 25 The basic suppressor system was then perturbed by a number of different procedures. In some experiments, normal intact T cells were treated with SLE plasma plus complement before the first culture; in other cases they were treated with SLE plasma plus complement after the first culture (see below).
Treatment of normal T cells with SLE plasma plus complement either before or after Con A activation. 1 X 107 normal T cells before or after activation by Con A for 60 h in 1 ml RPMI 1640 were mixed with 1 ml of SLE plasma, and kept at 4°C for 1 h. These T cells were then washed, resuspended in 750 jAI RPMI 1640, and incubated with 250 ,ul of rabbit complement (preabsorbed with sheep erythrocytes) at room temperature for another 3 h. Thereafter, these cells were washed three times and resuspended in culture medium, after which the viable cell yield was determined by trypan blue exclusion.
Inhibiting effect of sugars on the binding of SLE plasma to desialized T cells. Monosaccharides and polysaccharides were dissolved in RPMI 1640 containing 2% fetal bovine serum to give a concentration of 200 mM. 1 X 106 neuraminidase treated T cells were then floated in 100 Il of the sugar solution plus 100 ul of SLE plasma for 1 h at 4°C. Thereafter, these cells were analysed by indirect immunofluorescence with fluorescein isothiocyanate-conjugated rabbit anti-human IgM with the fluorescence microscope.
RESULTS
Binding of SLE plasma to intact or desialized normal T cells. Table I shows the results of staining of normal T cells, either intact or neuraminidase treated, with normal plasma or SLE plasma, and counterstaining with fluorescein-tagged antibody to human IgM. All plasma from nine patients with active SLE (pa- I If patients had mild subjective symptoms and had one or two of the criteria of activity as described in Methods, they were included in the mildly active group.
tients 1-9 in These are consistent with previous observations of our own (20, 21) , as well as with those of others (12, 15, 16) , that the presence of IgM SLE antibodies to intact T cells correlates well with disease activity. Treatment of normal T cells by neuraminidase was found to increase markedly the percentage of brightly staining cells with the active plasma (patients 1-9 in Table I ). When desialized normal T cells were used as target cells, the average increase in percentage of brightly staining cells was -56% with these nine active plasma patients. It should be further noted here that plasma from the other patients with less disease activity (patients 10-18), which could not bind to intact T cells, also demonstrated binding of IgM to an appreciable fraction of desialized normal T cells. In contrast, normal plasma did not stain the desialized T cells at all. These results suggest that some, but not all, antigenic determinants on the T cell surface recognized by SLE anti-T cell antibodies could be masked by sialic acid and can be exposed upon removal of sialic acid by neuraminidase.
The increase in the IgM binding to desialized T cells was most likely not due to proteolytic enzymes that could contaminate the preparation of neuraminidase, because prior treatment of the intact T cells with pronase, trypsin, or papain did not enhance the binding of SLE plasma to such treated T cells (Table II) . Rather, as shown in Table II , further treatment of neuraminidase treated T cells led to a decrease in the binding of SLE plasma to these cells. Thus, neuraminidase treatment of T cells appears to lead to enhancement of their binding to SLE anti-T cell antibodies by unmasking antigenic determinants by sialic acid. Moreover, the reduction in binding with proteolytic enzymes suggests that such determinants may be composed of asialo-glycoprotein.
Heterogeneity of SLE anti-T cell antibodies in view of their target cell specificities. The possible specificity of anti-T cell antibodies present in active SLE plasma was studied by prior adsorption of the plasma with either intact T cells or desialized T cells (Fig. 1) . The ability of active SLE plasma to bind to intact T cells was completely removed by prior adsorption with either intact T cells or neuraminidase treated desialized T cells. The binding of the plasma to desialized T cells was also abolished by prior adsorption with these cells but only slightly with intact T cells. To determine whether the binding activity of SLE plasma against neuraminidase treated T cells could be removed by prior adsorption of the plasma with increasing numbers of intact T cells, a dose-response experiment was performed. 1 ml plasma was adsorbed with increasing numbers of intact normal T cells, and the supernatant plasma after centrifugation was then examined for ability to bind to either intact or desialized T cells. As shown in Fig. 2 , adsorption with as few as 1 X 107 intact T cells completely removed the activity of SLE plasma against intact T cells, whereas the activity against neuraminidase treated T cells still remained in the supernatant plasma even after adsorption with 7 X 107 intact T cells. The remaining activity against desialized T cells when preadsorbed with 7 X 107 intact T cells was roughly the same as the remaining activity when preadsorbed with 1 X 107 intact T cells. These results cannot be explained if one assumes that SLE anti-T cell antibodies contain only one type of antibody. Rather, a possible explanation for the results is that SLE anti-T cell antibodies would comprise at least two types of antibodies with different target cell specificities; one type of these can bind to both intact and desialized T cells and another type can bind only to desialized T cells. (Fig. 3B) . On (Fig. 3A) . There was a lesser dsorbed plasma to either intact or neuraminidase treated degree of correlation (r =-0.58) between defective lls ( t Numbers of neuraminidase treated non-T cells used for adsorption (cells per milliliter of plasma).
1 ml SLE plasma were preadsorbed with 1 or 5 ml neuraminidase treated packed erythrocytes. ABO blood groups used for preadsorption are shown.
ence of IgG antibodies to intact or desialized T cells. The presence of IgG antibodies to either intact or desialized T cells did not correlate with suppressor T cell dysfunction (Fig. 3C, D) . Binding of SLE anti-desialized T cell antibodies to suppressor effector T cells. Our previous studies (2) have shown that the suppressor, but not helper, effector cells reside in the Con A-activated T cell population forming rosettes with autologous erythrocytes, whereas the reverse is true of the Con A-activated T cell population not forming autorosettes. In addition, Con Aactivated autorosetting T cells (which exert the suppressive effect) were shown to be stained with fluorescein-labeled peanut agglutinin, which indicates that Con A-induced suppressor effector cells possess abundant #-galactosyl residues exposed on the cell surface, not masked by sialic acid. Additional experiments were performed to determine whether the SLE antibodies to desialized T cells actually bound to suppressor effector cells defined by the autorosette technique. After Con A activation, normal T cells were washed in amethyl-D-mannoside, treated with SLE anti-T cell antibodies which had been adsorbed extensively with intact T cells (consequently, these antibodies should be specific for desialized T cells), followed by fluorescein isothiocyanate-conjugated F(ab')2 fragment of rabbit antihuman IgM or IgG, and then mixed with autologous erythrocytes to form rosettes. The results of such experiments are shown in Table V . Almost all cells stained with fluorescein-conjugated anti-IgM formed rosettes with autologous erythrocytes; the nonrosetting cells were not stained with the anti-IgM. In contrast, there existed very few cells that were stained with fluorescein-conjugated anti-IgG in the autorosetting T cell population; the nonrosetting cell population was preferably stained with the anti-IgG. These results plus those presented earlier (2) suggest that SLE IgM antibodies to desialized T cells preferentially bind to and kill suppressor effector cells.
Inhibition of reactivity of IgM antibodies to neuraminidase treated T cells by adding various sugars. It has been known that ,B-galactosyl residues are exposed on cell surfaces after neuraminidase treatment (5, 11, 23) . It is possible, therefore, that SLE antibodies to desialized T cells could recognize a terminal I-galactosyl residue of a sugar chain on the cell surface. If this is true, the binding of antibodies to desialized T cells should be inhibited by sugars. Table VI Previous studies (3, 15) have shown that an appreciable fraction of human thymocytes has receptors for peanut agglutinin; in contrast, very few human peripheral blood T cells bind peanut agglutinin unless pretreated with neuraminidase or activated during the course of immune stimulation. These observations suggest that during T cell maturation surface determi- Human suppressor effector cells are contained within the autorosetting population (2); these cells possess abundant ,B-galactosyl residues exposed on the cell surface, not masked by sialic acid (2) . We have found that SLE antibodies to desialized T cells selectively bind to, and kill, these suppressor effector cells. Consequently, defects in suppressor function observed in patients with SLE (25) (26) (27) (28) (29) could, at least in part, result from antibodies to desialized T cells. Indeed, when patients with SLE were studied simultaneously with regard to (a) suppressor cell activity produced by their own T lymphocytes and (b) the presence of antibodies to either desialized normal T cells or intact normal T cells, defects in the suppressor T cell activity observed in lymphocytes from patients with SLE correlated well with the presence of antibodies directed at desialized, but not intact, T cells.
It has been shown that f,-galactosyl residues are exposed on the cell surface after treatment of cells with neuraminidase (5, 11, 23) . Therefore, it is expected that the antigenic determinants recognized by the SLE antibodies to desialized T cells could be associated with s-galactosyl residues. D-(+)-lactose was the most potent inhibitor against the activity of SLE antibodies to desialized T cells, whereas a-D-glucose, D-(+)-mannose, N-acetyl-D-glucosamine and N-acetyl-D-galactosamine were only slightly inhibitory against the activity. These results suggest that ,-galactosyl residues may be an important part of the antigenic determinants recognized by antibodies to desialized T cells. Moreover, it was noted that further treatment of desialized T cells with proteolytic enzymes almost completely inhibited the binding of SLE plasma to these cells. Such an observation strongly suggests that antibodies to desialized T cells may recognize asialo-glycoprotein on the cell surface. Additional characterization and determination of the molecular structure of determinants with which antibodies to T cell subsets interact should lead to further insight into the details of normal immune regulation and defects in such regulation in patients.
